Europe Mucopolysaccharidoses (mps) Treatment Market Size & Outlook

The mucopolysaccharidoses (mps) treatment market in Europe is expected to reach a projected revenue of US$ 1,411.1 million by 2027. A compound annual growth rate of 6.6% is expected of Europe mucopolysaccharidoses (mps) treatment market from 2021 to 2027.
Revenue, 2020 (US$M)
$904.3
Forecast, 2027 (US$M)
$1,411.1
CAGR, 2021 - 2027
6.6%
Report Coverage
Europe

Europe mucopolysaccharidoses (mps) treatment market, 2015-2027 (US$M)

Europe

Related Markets

Europe mucopolysaccharidoses (mps) treatment market highlights

  • The Europe mucopolysaccharidoses (mps) treatment market generated a revenue of USD 904.3 million in 2020.
  • The market is expected to grow at a CAGR of 6.6% from 2021 to 2027.
  • In terms of segment, ert was the largest revenue generating treatment type in 2020.
  • ERT is the most lucrative treatment type segment registering the fastest growth during the forecast period.
  • Country-wise, UK is expected to register the highest CAGR from 2021 to 2027.

Europe data book summary

Market revenue in 2020USD 904.3 million
Market revenue in 2027USD 1,411.1 million
Growth rate6.6% (CAGR from 2020 to 2027)
Largest segmentErt
Fastest growing segmentERT
Historical data covered2015 - 2019
Base year for estimation2020
Forecast period covered2021 - 2027
Quantitative unitsRevenue in USD million
Market segmentationERT, HSCT

Other key industry trends

  • In terms of revenue, Europe region accounted for 36.1% of the global mucopolysaccharidoses (mps) treatment market in 2020.
  • Globally, Europe is projected to lead the regional market in terms of revenue in 2027.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 993.4 million by 2027.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Mucopolysaccharidoses (MPS) Treatment Market Companies

Name Profile # Employees HQ Website

Europe mucopolysaccharidoses (mps) treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mucopolysaccharidoses (mps) treatment market will help companies and investors design strategic landscapes.


Ert was the largest segment with a revenue share of 79.38% in 2020. Horizon Databook has segmented the Europe mucopolysaccharidoses (mps) treatment market based on ert, hsct covering the revenue growth of each sub-segment from 2015 to 2027.


  • Europe Mucopolysaccharidoses (MPS) Treatment Treatment Type Outlook (Revenue, USD Million, 2015-2027)
    • ERT
    • HSCT
  • Europe Mucopolysaccharidoses (MPS) Treatment Indication Outlook (Revenue, USD Million, 2015-2027)
    • MPS Type I
    • MPS Type II
    • MPS Type IV
    • MPS Type VI
    • MPS Type VII
    • Others (Type IX & Type III)

Reasons to subscribe to Europe mucopolysaccharidoses (mps) treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe mucopolysaccharidoses (mps) treatment market databook

  • Our clientele includes a mix of mucopolysaccharidoses (mps) treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe mucopolysaccharidoses (mps) treatment market, including forecasts for subscribers. This continent databook contains high-level insights into Europe mucopolysaccharidoses (mps) treatment market from 2015 to 2027, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe mucopolysaccharidoses (mps) treatment market size, by country, 2015-2027 (US$M)

Europe Mucopolysaccharidoses (MPS) Treatment Market Share, 2020 & 2027 (US$M)

Europe mucopolysaccharidoses (mps) treatment market size, by country, 2015-2027 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more